Cannabis Use Clinical Trial
— CannTeenAOfficial title:
Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?
NCT number | NCT04851392 |
Other study ID # | 5929/005 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 11, 2019 |
Est. completion date | June 16, 2021 |
Verified date | September 2021 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).
Status | Completed |
Enrollment | 48 |
Est. completion date | June 16, 2021 |
Est. primary completion date | June 16, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 29 Years |
Eligibility | Inclusion Criteria: - Adolescents: Aged 16-17 - Adults: Aged 26-29 years - Self-reported cannabis use between 0.5 and 3 days/week, averaged over the last 3 months - Adults: Body mass index (BMI) between 18.5 and 29.9 - Adolescents: BMI between 2nd percentile and 98th percentile - Self-reported ability to consume approximately half a typical joint of cannabis by themselves within 20 minutes - Willing to be cannulated and have four blood samples taken at every acute session - Right-handed Exclusion Criteria: - Females: Pregnant or breast-feeding - Adults: Before the age of 18, had a period of 3 or more months when cannabis was used once per week or more frequently. - Severe cannabis use disorder (DSM-5) - Illicit drug use of any specific drug more than twice per month, averaged over the last 3 months - Receiving treatment (pharmacological or psychological) for a mental health problem within the last month - Lifetime psychosis - Lifetime psychosis of any immediate family member - Hypertension (systolic > 160 or diastolic > 100) - Dependent on tobacco or vaping nicotine (> 1 on the Heaviness of Smoking Index) - Currently taking a psychotropic medication that will likely affect dependent variables or interact with cannabis - Any physical or mental health condition, any medication, or any treatment, that the study doctor considers to be an exclusion - MRI contraindications - Significant asthma or respiratory problems - severity judged clinically - Self-reported moderate/severe acute unpleasant effects from cannabis which occur often or always - Positive alcohol breathalyser reading at any acute session (rearrange session) - Self-reported use of alcohol within 24 hours at any acute session (rearrange session) - Self-reported use of illicit drugs (including cannabis) within 72 hours at any acute session (rearrange session) - Positive saliva drug screen at any acute session (rearrange session) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University College London | London |
Lead Sponsor | Collaborator |
---|---|
University College, London | Invicro, Medical Research Council |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psychotomimetic effect | Measured by total Psychotomimetic States Inventory (PSI) score | Measured once, 2 hours after the start of drug administration, on each drug condition | |
Primary | Verbal episodic memory | Measured by delayed prose recall performance | Measured once, 2 hours after the start of drug administration, on each drug condition | |
Primary | Strength of subjective drug effect | Measured by self-reported 'feel drug effect', rated from 0 (not at all) to 10 (extremely) | Measured 20 minutes after the start of drug administration, on each drug condition | |
Secondary | Self-reported subjective effects | Feel drug effect, like drug effect, dislike drug effect, alert, want to have cannabis, happy, relaxed, anxious, paranoid, mentally impaired, stoned, dry mouth, unmotivated, intensified sensory perception, want to listen to music, want food, want to see friends, rated from 0 (not at all) to 10 (extremely) | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition | |
Secondary | Functional magnetic resonance imaging (fMRI) measured neural correlates | Reward anticipation and reward feedback, response inhibition, spatial working memory, and resting-state | Measured between 40 minutes and 1 hour & 20 minutes after the start of drug administration, on each drug condition | |
Secondary | Magnetic resonance spectroscopy | Measuring glutamate levels in the dorsal striatum | Measured 1 hour & 30 minutes after the start of drug administration, on each drug condition | |
Secondary | Positive and negative syndrome scale | Kay et al. (1987). Higher scores reflect stronger positive and negative symptoms. | Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition | |
Secondary | Effort-related decision-making (i.e. amotivation) | Measured by the physical effort task ('apple-gathering' task) as described in Husain & Roiser (2018) | Measured 2 hours & 20 minutes after the start of drug administration, on each drug condition | |
Secondary | Pleasure processing | Measured by subjective liking in response to chocolate, music and cartoons, rated from 0 (not at all) to 10 (extremely), similar to Lawn et al. (2015) | Measured 2 hours & 30 minutes after the start of drug administration, on each drug condition | |
Secondary | Visual attentional bias to cannabis and food stimuli | Measured by the visual dot-probe task, as described in Morgan et al. (2010) | Measured 2 hours & 10 minutes after the start of drug administration, on each drug condition | |
Secondary | Heart rate | Measuring heart rate | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition | |
Secondary | Blood pressure | Measuring systolic and diastolic blood pressure. | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition | |
Secondary | Exogenous and endogenous cannabinoid levels in plasma | Measuring THC and CBD and metabolites; and endocannabinoids | Measured -30 minutes, 20 minutes, 30 minutes, and 2 hours & 40 minutes after the start of drug administration, on each drug condition | |
Secondary | Dissociative states scale | Bremner et al. (1998). Higher scores reflect greater dissociation. | Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03253926 -
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
|
Phase 1/Phase 2 | |
Completed |
NCT04060602 -
Personalized Feedback Intervention to Reduce Risky Cannabis Use.
|
N/A | |
Completed |
NCT01212081 -
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
|
||
Recruiting |
NCT04988490 -
Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
|
||
Recruiting |
NCT05188404 -
Aging and Marijuana: Benefits, Effects, and Risks
|
||
Completed |
NCT03662737 -
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
|
||
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Active, not recruiting |
NCT04374773 -
Effects of Pregnancy-associated Hormones on THC Metabolism in Women
|
Phase 4 | |
Completed |
NCT04316741 -
Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use
|
N/A | |
Recruiting |
NCT05396638 -
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05309226 -
Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
|
||
Recruiting |
NCT03859089 -
Cannabis for Opioid Substitution Trial
|
||
Recruiting |
NCT05849636 -
Alerta Cannabis: Evaluation of Web-based Tailored Intervention
|
N/A | |
Enrolling by invitation |
NCT05521321 -
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit
|
N/A | |
Recruiting |
NCT05119244 -
Environment and Lung Cancer
|
N/A | |
Recruiting |
NCT04841655 -
Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
|
||
Terminated |
NCT04100590 -
Eye Tracking as a Biomarker of Cannabis Effects
|
Phase 2 | |
Completed |
NCT05167097 -
Mindsets and the Effectiveness of a Brief Intervention - Replication
|
N/A | |
Recruiting |
NCT04114903 -
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
|